Precision medicine advancements in glioblastoma: A systematic review.

IF 4.7 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2023-06-01 eCollection Date: 2023-01-01 DOI:10.37796/2211-8039.1403

Karan Iyer, Shubham Saini, Suman Bhadra, Sohini Kulavi, Jaya Bandyopadhyay

{"title":"Precision medicine advancements in glioblastoma: A systematic review.","authors":"Karan Iyer, Shubham Saini, Suman Bhadra, Sohini Kulavi, Jaya Bandyopadhyay","doi":"10.37796/2211-8039.1403","DOIUrl":null,"url":null,"abstract":"Background: Glioblastoma multiforme, commonly known as GBM or glioblastoma is a grade IV astrocytoma. Brain tumors are difficult to treat and lead to poor prognosis and survival in patients. Gliomas are categorized into four different grades among which GBM is the worst grade primary brain tumor with a survival of less than a year. The genomic heterogeneity of the brain tumor results in different profiles for patients diagnosed with glioblastoma. Precision medicine focuses on this specific tumor type and suggests specialized treatment for better prognosis and overall survival (OS).Purpose: With the recent advancements in Genome-Wide Studies (GWS) and various characterizations of brain tumors based on genetic, transcriptomic, proteomic, epigenetic, and metabolomics, this review discusses the advancements and opportunities of precision medicine therapeutics, drugs, and diagnosis methods based on the different profiles of glioblastoma.Methods: This review has exhaustively surveyed several pieces of works from various literature databases.Conclusion: It is evident that most primary brain tumors including glioblastoma require specific and precision therapeutics for better prognosis and OS. In present and future, molecular understanding and discovering specific therapies are essential for treatment in the field of neurooncology.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":" ","pages":"1-13"},"PeriodicalIF":4.7000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627207/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37796/2211-8039.1403","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Glioblastoma multiforme, commonly known as GBM or glioblastoma is a grade IV astrocytoma. Brain tumors are difficult to treat and lead to poor prognosis and survival in patients. Gliomas are categorized into four different grades among which GBM is the worst grade primary brain tumor with a survival of less than a year. The genomic heterogeneity of the brain tumor results in different profiles for patients diagnosed with glioblastoma. Precision medicine focuses on this specific tumor type and suggests specialized treatment for better prognosis and overall survival (OS).

Purpose: With the recent advancements in Genome-Wide Studies (GWS) and various characterizations of brain tumors based on genetic, transcriptomic, proteomic, epigenetic, and metabolomics, this review discusses the advancements and opportunities of precision medicine therapeutics, drugs, and diagnosis methods based on the different profiles of glioblastoma.

Methods: This review has exhaustively surveyed several pieces of works from various literature databases.

Conclusion: It is evident that most primary brain tumors including glioblastoma require specific and precision therapeutics for better prognosis and OS. In present and future, molecular understanding and discovering specific therapies are essential for treatment in the field of neurooncology.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胶质母细胞瘤的精准医学进展:系统综述

背景：多形性胶质母细胞瘤，通常称为GBM或胶质母细胞细胞瘤，是一种IV级星形细胞瘤。脑肿瘤治疗困难，导致患者预后和生存率差。胶质瘤分为四个不同级别，其中GBM是最差级别的原发性脑肿瘤，生存期不到一年。脑肿瘤的基因组异质性导致被诊断为胶质母细胞瘤的患者出现不同的结果。精准医学专注于这种特定的肿瘤类型，并建议进行专门治疗以获得更好的预后和总体生存率（OS）目的：随着全基因组研究（GWS）的最新进展以及基于遗传、转录组学、蛋白质组学、表观遗传学和代谢组学的脑肿瘤的各种特征，这篇综述讨论了基于胶质母细胞瘤不同类型的精准医学治疗、药物和诊断方法的进展和机遇。方法：本综述对不同文献数据库中的几篇作品进行了详尽的调查。结论：很明显，包括胶质母细胞瘤在内的大多数原发性脑肿瘤都需要特殊而精确的治疗方法来改善预后和OS。在现在和未来，分子理解和发现特定疗法对于神经肿瘤学领域的治疗至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464

期刊介绍： ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.